BC Innovations | Aug 4, 2016
Targets & Mechanisms

Cereblon ambition

Most anti-cancer strategies aim to block overactive proteins by directly inhibiting their activity, but a growing number of companies are developing ways to tag the proteins for destruction by recruiting the enzymes that shuttle them...
BC Innovations | Jul 28, 2016
Distillery Therapeutics

Therapeutics: Glutathione S-transferase π 1 (GSTP1); cereblon (CRBN)

Cancer INDICATION: Acute myelogenous leukemia (AML) Cell culture, in vitro and patient sample studies identified a promoter of CRBN-mediated GSTP1 degradation that could help treat AML. Screening of thalidomide analogs in human AML cell lines...
BC Innovations | Jun 9, 2016
Distillery Therapeutics

Therapeutics: Glutathione S-transferase pi 1 (GSTP1)

Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting GSTP1 could help treat triple-negative breast cancer (TNBC). Levels of GSTP1 were higher in TNBC cell lines and TNBC tumor samples from...
BC Week In Review | Apr 15, 2013
Company News

Oncor, The Johns Hopkins University deal

Oncor licensed a patent from the university for genetic diagnosis of prostate cancer. The company said the technology demonstrated that loss of expression of the glutathione-S-transferase gene (GSTP1) predicts development of prostate cancer. GSTP1 expression...
BC Week In Review | Feb 4, 2013
Company News

Epigenomics, Predictive Biosciences sales and marketing update

The partners said Predictive Biosciences launched a biopsy test to diagnose prostate cancer in the U.S. that incorporates Epigenomics' glutathione S-transferase pi 1 ( GSTP1 ) DNA methylation marker. In 2010, Predictive exercised a 2009 option to...
BC Innovations | Aug 11, 2011
Targets & Mechanisms

ROS overload

Boston researchers have identified a molecule that kills tumors by taking the already high level of reactive oxygen species in cancer cells and upping it further. The molecule had efficacy in a wide range of...
BC Week In Review | May 4, 2009
Company News

Epigenomics, Predictive Biosciences deal

Predictive biosciences received a non-exclusive, U.S. license to develop and commercialize Epigenomics' glutathione S-transferase P1-1 ( GSTP1 ; GST P1-1 ) DNA methylation biomarker in molecular-based laboratory developed tests to diagnose prostate cancer. Further terms were not...
BC Innovations | Apr 16, 2009
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Sarcoma Microsomal glutathione S-transferase 1 (MGST1) In vitro studies suggest that MGST1 expression could help predict response to chemotherapy and guide...
Items per page:
1 - 8 of 8